Navigation Links
Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy
Date:5/8/2012

nts expressed or implied by the forward-looking statements.  Such potential risks and uncertainties include, without limitation, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.  These statements, including patient data, are based on information currently available to the Company's management and future patient results may differ from present results.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:

James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com

Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com

Marc Robins
877.276.2467
mr@aethlonmedical.com

 

 


'/>"/>
SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Aethlon Medical to Present at the 2009 RedChip Small-Cap Investor Conference on June 16, 2009
2. Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference
3. Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus
4. Aethlon Medical Discloses Live Webcast of Todays BIOCOM Presentation
5. Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs
6. Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program
7. Aethlon Medical to Present at Rodman & Renshaw Annual Global Investment Conference
8. Aethlon Medical Reestablishes Biodefense Programs
9. Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships
10. Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors
11. Aethlon Medical Names Rod Kenley President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)...  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... Phase II proof of concept clinical study investigating ... monotherapy in the treatment of chronic pruritus in ... and clinically meaningful improvement from baseline by tradipitant ... a 100mm unit Visual Analog Scale (VAS) for ...
(Date:3/4/2015)... Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the ... China, today announced its financial results for the fourth ... Quarter 2014 Financial Highlights , Total sales ... or 36.8% excluding the impact of foreign currency exchange ... the same quarter of 2013. , Gross profit ...
(Date:3/4/2015)... GSI Group Inc. (NASDAQ: GSIG ) (the ... of precision photonics and motion control components and subsystems ... today reported financial results for the fourth quarter and ... in this press release are GAAP measures from continuing ... of 2014, GSI generated revenue of $94.0 million, an ...
Breaking Medicine Technology:Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 4Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 5Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 6Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 7China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 2China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 3China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 4China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 5China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 6China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 7China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 8China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 9China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 10China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 11China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 12China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 13China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 14China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 15China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 16China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 17China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 18China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 19China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 20China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 21China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 22GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 2GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 3GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 4GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 5GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 6GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 7GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 8GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 9
... human clinical data highlight safety profile of BSI-201 in ... subjects with advanced solid tumors ... a,privately held biopharmaceutical company developing novel cancer therapies,today announced that ... the 2008 American Society of Clinical Oncology annual,meeting in Chicago., ...
... ASCO Showed Acceptable Tolerability Profile, ... Low Incidence of Grade 3 and 4 Neuropathy, ... eribulin mesylate (E7389) demonstrated activity in a,heavily pretreated population ... to results of a multi-center Phase II clinical,trial. The ...
Cached Medicine Technology:BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3
(Date:3/4/2015)... New York (PRWEB) March 04, 2015 ... ) that allege the statin drug caused patients to ... the U.S. District Court, District of South Carolina. According ... be convened on March 26, 2015 at 10:00 a.m. ... directed to submit a Joint Status report to the ...
(Date:3/4/2015)... 04, 2015 Cook For Your Life ... teaches healthy cooking to people touched by cancer, is ... The program, run by founder Ann Ogden, will be ... Management. The unique partnership will expand the program from ... CFYL in 2007. After going through her own cancer ...
(Date:3/4/2015)... growing influence of movies, television, video games and the internet ... with the increasingly frantic lifestyle of modern parents, it can ... what kids are into these days. It seems that every ... , The same is also true for drugs and alcohol. ... talk about them, are constantly changing. These tips put a ...
(Date:3/4/2015)... 2015 Starting February 2015, Dr. Joseph ... procedures at their new location in Surrey. , In ... and Dr. Gabriel Chu also provide comprehensive ophthalmology services, ... named Fraser Valley Cataract and Laser (FVCL). This state ... College of Physicians and Surgeons of British Columbia. Fraser ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 The print ... of The San Francisco Chronicle with a circulation of ... readers. Its digital component is distributed nationally through a ... top news sites and partner outlets. To explore the ... , Milorganite is composed of heat-dried microbes that ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 3Health News:Drexel University and Cook for Your Life Team Up 2Health News:Drexel University and Cook for Your Life Team Up 3Health News:Drexel University and Cook for Your Life Team Up 4Health News:Drexel University and Cook for Your Life Team Up 5Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2Health News:King LASIK relocates to Surrey, British Columbia 2
... Awards Honor Unsung Heroes of Violence Prevention, ... history,with drug abuse, incarceration, and homelessness inspires her ... families. Orlando Ramos brings the,power of education and ... Billie Weiss conducts pioneering public-health research,that helps community- ...
... Nov. 12 Karen Ignagni, President,and CEO of America,s ... response to the new health care reform proposal,released by ... for health care reform. We commend Senator Baucus for,putting ... health,care challenges facing the nation. We look forward to ...
... The American Society of Plastic Surgical Nurses presented its ... a Rutgers College of Nursing faculty member, and her ... 1. , Rankin, clinical associate professor at The ... New Jersey, and her co-authors, Carrie Carretta, an advanced ...
... runs for Prime Minister or President should have an independent ... doctor on bmj.com today. , Lord David Owen, ... says that millions of people are affected by the decisions ... an obligation to the general public to ensure that their ...
... see doctors far more frequently, study finds , , WEDNESDAY, ... failure have many more doctor visits and take more ... , They based their conclusion on an analysis of ... of the beneficiaries was 70.7 years, while the average ...
... states plus Puerto Rico and District of Columbia get failing ... comes to premature birth rates, the United States rates a ... of Columbia get failing grades. , That,s the sobering conclusion ... Report Card , released Wednesday. Not a single state earned ...
Cached Medicine News:Health News:Three Community Leaders to Receive Foundation's 2008 California Peace Prize 2Health News:Three Community Leaders to Receive Foundation's 2008 California Peace Prize 3Health News:World leaders must be more open about their health 2Health News:Heart Failure Accounts for 37% of Medicare Spending 2Health News:U.S. Gets a 'D' for Preterm Birth Rates 2
With ten colors available, Spectrums line of Color-Coded Fiberoptic Light Cables makes it easy to track by department....
... gives you the exceptional performance you need at ... illumination, comfort and durability youd expect from headlights ... headlight. It features our thinnest cable and adjusts ... flexibility. Now when you reach for a headlight ...
... Sunnex Celestial Star™ light ... applications. The flexible design ... and positioning. The space-saving ... many facilities including emergency ...
The Next Generation in Single Lamp Technology, Advanced Optics & Reflector Design, Extended Depth of Field, 54" Useable Column of Light, High Intensity, Cool Beam Temperature...
Medicine Products: